Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2017
Price : $35 *
At a glance
- Drugs Prasterone (Primary)
- Indications Atrophic vaginitis
- Focus Registrational; Therapeutic Use
- Sponsors Endoceutics
- 09 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
- 02 Oct 2014 According to the ClinicalTrial.gov record, planned end date changed from 1 Jan 2015 to 1 Apr 2015.
- 02 Oct 2014 According to the ClinicalTrial.gov record,status changed from recruiting to active, no longer recruiting.